Buy Stivarga Online

Stivarga is an oral cancer medication containing regorafenib, a multikinase inhibitor used in specific later-line cancer treatment plans. It can be bought online, with current Stivarga price information shown during ordering and strength or quantity choices matched to the directions from your oncology team. Stivarga tablets are commonly described as 40 mg film-coated tablets, so tablet count and cycle timing are important before completing a fill.

Regorafenib treatment requires careful monitoring because it can affect the liver, blood pressure, skin, bleeding risk, and wound healing. Use the medication only under the direction of an oncology clinician, and keep lab appointments and symptom reporting plans current throughout treatment.

Stivarga Price, 40 mg Tablets, and Quantity Planning

The Stivarga price should be reviewed against the strength, tablet count, and total quantity being purchased. Most official product information describes Stivarga 40 mg film-coated tablets, but the number of tablets needed for a cycle depends on the regimen your oncology team has chosen. A larger bottle can still represent a limited treatment period when several tablets are taken on dosing days.

When evaluating Stivarga cost, focus on the total fill amount rather than only a unit figure. This is especially useful for cash-pay customers, people managing Stivarga without insurance, or anyone coordinating treatment around clinic reassessments. If paperwork uses the nonproprietary name, regorafenib, match regorafenib price information to the same active ingredient, strength, and tablet quantity.

Quick tip: Count tablets against the full treatment cycle, not just the number of days in a month.

How to Order Stivarga Online

To order Stivarga online, choose the strength and quantity that match the current treatment instructions. Use the same legal name and clinic information associated with your oncology care, and keep recent treatment documents available in case order details need clarification. We may review order information to help ensure the requested medication, strength, and quantity are aligned before the pharmacy supplies it.

Stivarga US delivery from Canada may be relevant for customers seeking a cash-pay cross-border path. If the shipment uses prompt, express shipping, keep tracking details available and store the labeled bottle correctly as soon as it arrives. Do not transfer tablets into a pill organizer unless the oncology team specifically says it is appropriate, because moisture protection matters for this medication.

• Match the active ingredient: Stivarga contains regorafenib.
• Choose the correct strength when Stivarga 40 mg is required.
• Confirm the total tablet count for the planned cycle.
• Keep clinic contact details current for order clarification.
• Plan ahead because oncology refills often need coordination.

For broader browsing within oncology medicines, the Cancer Treatments category can help keep related products in one place. Your oncology team remains the source for treatment selection, dose adjustments, pauses, and when to restart therapy after side effects or procedures.

What Stivarga Treats

Stivarga is used in certain adults with metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and anti-EGFR therapy when appropriate. It is also used for unresectable or metastatic gastrointestinal stromal tumor after prior imatinib and sunitinib treatment, and for hepatocellular carcinoma in people previously treated with sorafenib. These use contexts come from official labeling and depend on individual clinical history.

This medicine is not a general chemotherapy tablet for every cancer type. It is a targeted therapy that blocks several kinases, which are enzymes involved in tumor growth, tumor blood vessel formation, and the cancer cell environment. Your care team considers tumor type, prior therapy, liver function, blood pressure, bleeding history, performance status, and treatment goals before continuing regorafenib.

Customers organizing condition-specific information may find the Colorectal Cancer, Gastrointestinal Stromal Tumor, and Liver Cancer sections useful for related context. For additional educational reading, the article on understanding colorectal cancer explains common disease concepts in patient-friendly language.

Stivarga Dosage Basics and Tablet Use

The labeled adult schedule is commonly daily treatment for 21 days followed by 7 days off, repeated in 28-day cycles. The exact Stivarga dosage may be started, reduced, paused, or stopped by the oncology team based on side effects, liver tests, blood pressure, and overall tolerability. Do not change the number of tablets or restart after a pause without clinical direction.

Official patient instructions state that tablets should be taken after a low-fat breakfast and swallowed whole with water. Do not crush, chew, split, or dissolve the tablets. Taking doses consistently with the recommended meal pattern helps reduce variability and keeps the plan easier to follow across treatment cycles.

If a dose is missed, labeling generally instructs taking it on the same day as soon as remembered. If it is the next day, skip the missed dose and return to the usual schedule. If vomiting occurs after taking Stivarga, do not take an extra tablet unless the oncology team gives different instructions.

Because each tablet is 40 mg in common product information, several tablets may be used to make up a daily amount. That is why Stivarga tablets, strength, quantity, and refill date should be reviewed together. A written calendar or clinic-provided cycle sheet can reduce accidental extra doses or missed rest days.

Storage, Travel, and Handling

Store Stivarga at room temperature in the original bottle, tightly closed and protected from moisture. Keep the desiccant in the bottle if one is supplied, because it helps control humidity. Official handling instructions also say to discard unused tablets seven weeks after opening the bottle, so write the opening date somewhere safe.

Avoid bathroom cabinets, kitchen sinks, hot cars, and other places with heat or moisture. Keep the bottle away from children and pets. If caregivers help with medication routines, they should know that this is an oral cancer medicine and should follow clinic instructions for safe handling.

During travel, keep the labeled container in carry-on luggage and bring enough tablets for the planned time away. A current medication list and clinic note can help answer questions during security checks or unexpected medical visits. Refill planning should account for travel dates, cycle timing, and the seven-week discard rule after opening.

Why it matters: Moisture protection and discard timing can affect both safety and refill planning.

Side Effects, Boxed Warning, and When to Call

Stivarga side effects can be serious, and early reporting may prevent complications. Common effects include hand-foot skin reaction, fatigue, diarrhea, decreased appetite, weight loss, high blood pressure, mouth irritation, rash, dry skin, hoarseness, and voice changes. The care team may recommend skin care, blood pressure tracking, antidiarrheal strategies, nutrition support, or temporary treatment interruption depending on severity.

Stivarga carries a boxed warning for severe and sometimes fatal liver toxicity. Liver tests are usually checked before treatment starts and repeated during therapy, especially early in the course. Call the oncology team promptly for yellowing skin or eyes, dark urine, unusual tiredness, right-sided abdominal pain, nausea that worsens suddenly, or symptoms that feel severe or unexpected.

Other serious risks include bleeding, gastrointestinal perforation or fistula, severe infection, heart ischemia or heart attack, high blood pressure crisis, reversible posterior leukoencephalopathy syndrome, severe skin reactions, and wound-healing problems. Seek urgent care for black stools, coughing blood, severe stomach pain, chest pain, shortness of breath, confusion, sudden vision changes, weakness on one side, fainting, or a rapidly spreading rash.

Tell your oncology team about recent surgery, upcoming dental work, pregnancy, plans to become pregnant, or breastfeeding. Regorafenib can harm an unborn baby, and contraception precautions may be needed during treatment and for a period after the last dose. Wound-healing concerns are also important, because the medicine may need to be held around certain procedures.

Interactions and Monitoring During Treatment

Regorafenib is affected by CYP3A4, an enzyme pathway that processes many medicines. Strong CYP3A4 inhibitors can increase exposure, while strong inducers can reduce exposure. Examples may include certain antifungals, antibiotics, antivirals, seizure medicines, and herbal products such as St. John’s wort.

Blood thinners, antiplatelet medicines, and other products that raise bleeding risk need careful attention. People taking warfarin or similar medicines may need closer lab monitoring. Grapefruit products may also affect drug levels, so ask the care team whether they should be avoided during regorafenib treatment.

Monitoring commonly includes liver function tests, blood pressure checks, skin and foot assessments, mouth checks, weight tracking, and symptom review. Home blood pressure readings, photos of hand-foot skin changes, and a simple diary of diarrhea, appetite, pain, and fatigue can make clinic visits more productive. Bring an updated list of all prescription medicines, over-the-counter products, vitamins, and supplements to each appointment.

Brand, Manufacturer, and Regorafenib Name

Stivarga is the brand name for regorafenib. The Stivarga manufacturer information identifies the medicine as a film-coated tablet for oral use, with regorafenib as the active ingredient. Clinical documents, pharmacy labels, and insurance or cash-pay notes may use either the brand name or the active ingredient, so it is useful to recognize both names.

Brand and generic naming can differ by market, and country-specific regulatory status does not change the need to match the exact medication chosen by the oncology team. If you see regorafenib tablets referenced in care documents, confirm the strength, tablet count, and brand or product name before placing a fill. This helps prevent confusion between active ingredient language and the actual bottle being supplied.

Regorafenib is not the same medicine as other targeted therapies used in colorectal cancer, gastrointestinal stromal tumor, or liver cancer. Medicines in this broader area can have different targets, dosing schedules, food instructions, interactions, and safety warnings. Do not substitute another cancer medicine unless the oncology team changes the treatment plan.

Related Oncology Choices to Discuss

Regorafenib may appear alongside other later-line or targeted therapies in oncology discussions, but each medicine has a different label and safety profile. For liver cancer pathways, sorafenib is associated with Nexavar. For certain liver cancer situations, cabozantinib is associated with Cabometyx. Treatment order and suitability depend on prior therapies, liver function, blood pressure, bleeding risk, and tumor features.

For metastatic colorectal cancer with a BRAF V600E mutation, encorafenib may be discussed in combination-based treatment planning; the Braftovi product can help you identify that related brand. The article on Braftovi cancer therapy uses offers additional context for that separate treatment pathway. These medicines are not interchangeable with Stivarga.

General cancer articles in the Cancer Articles section may help patients and caregivers prepare better questions for clinic visits. Use those educational materials as background only, and rely on your oncology team for individualized decisions about sequencing, dose changes, monitoring, and side-effect management.

Authoritative Sources

Patient safety and use information from the manufacturer: STIVARGA patient information.

Healthcare professional information from the manufacturer: STIVARGA healthcare professional information.

This content is for informational purposes only and is not a substitute for professional medical advice.